Terminated PHASE2 INTERVENTIONAL NCT00313482

PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC

A Phase II Trial of Docetaxel/Prednisone in Combination With Sargramostim as Treatment for Hormone-refractory Prostate Cancer

Sponsor: Bayer

Conditions Hormone Refractory Prostate Cancer

Interventions Docetaxel Prednisone Sargramostim

Updated 5 times since 2017 Last updated: May 9, 2012 Started: Apr 30, 2006 Primary completion: Aug 31, 2008 Completion: Aug 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual

Other terminated trials from Bayer

See all terminations from Bayer

This PHASE2 trial investigates Hormone Refractory Prostate Cancer and is currently terminated or withdrawn. Bayer leads this study, which shows 5 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Apr 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
Veeda Oncology

Data source: Veeda Oncology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Columbus, United States